(R)-Amisulpride | CAS# 71675-90-6 | atypical antipsychotic

MedKoo Cat#: 573855 | Name: (R)-Amisulpride

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Amisulpride, (R)-, is an atypical antipsychotic used to treat psychosis in schizophrenia and episodes of mania in bipolar disorder.

Chemical Structure

(R)-Amisulpride

CAS#71675-90-6 (R-isomer)

Theoretical Analysis

MedKoo Cat#: 573855

Name: (R)-Amisulpride

CAS#: 71675-90-6 (R-isomer)

Chemical Formula: C17H27N3O4S

Exact Mass: 369.1722

Molecular Weight: 369.48

Elemental Analysis: C, 55.26; H, 7.37; N, 11.37; O, 17.32; S, 8.68

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 320.00	2 Weeks
10mg	USD 580.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

81342-13-4 (HCl) 71675-85-9 (free base) 71675-92-8 (S-isomer) 71675-90-6 (R-isomer) 2129505-46-8 ( R-isomer HCl)

Synonym

(R)-Amisulpride, Amisulpride, (R)-; Aramisulpride

IUPAC/Chemical Name

Benzamide, 4-amino-N-(((2R)-1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-, (R)-

InChi Key

NTJOBXMMWNYJFB-GFCCVEGCSA-N

InChi Code

1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)/t12-/m1/s1

SMILES Code

CCN1CCC[C@@H]1CNC(=O)c2cc(c(cc2OC)N)S(=O)(=O)CC

Appearance

Off-White to Yellow Solid

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Hygroscopic; Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Chloroform (Slightly), Methanol (Very Slightly, Sonicated)

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 369.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hadryś T, Rymaszewska J. Amisulpride - is it as all other medicines or is it different? An update. Psychiatr Pol. 2020 Oct 31;54(5):977-989. English, Polish. doi: 10.12740/PP/OnlineFirst/109129. Epub 2020 Oct 31. PMID: 33529280. 2: Amisulpride. Am J Health Syst Pharm. 2020 Nov 16;77(23):1917-1918. doi: 10.1093/ajhp/zxaa292. PMID: 33196816. 3: Kang C, Shirley M. Amisulpride: A Review in Post-Operative Nausea and Vomiting. Drugs. 2021 Feb;81(3):367-375. doi: 10.1007/s40265-020-01462-1. Epub 2021 Mar 3. PMID: 33656662. 4: Johnsen E, Kroken RA, Løberg EM, Rettenbacher M, Joa I, Larsen TK, Reitan SK, Walla B, Alisauskiene R, Anda LG, Bartz-Johannessen C, Berle JØ, Bjarke J, Fathian F, Hugdahl K, Kjelby E, Sinkeviciute I, Skrede S, Stabell L, Steen VM, Fleischhacker WW. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi- randomised trial. Lancet Psychiatry. 2020 Nov;7(11):945-954. doi: 10.1016/S2215-0366(20)30341-2. PMID: 33069317. 5: Schmidt-Kraepelin C, Feyerabend S, Engelke C, Riesbeck M, Meisenzahl-Lechner E, Verde PE, Correll CU, Kluge M, Makiol C, Neff A, Lange C, Englisch S, Zink M, Langguth B, Poeppl TB, Reske D, Gouzoulis-Mayfrank E, Gründer G, Hasan A, Brockhaus-Dumke A, Jäger M, Baumgärtner J, Leucht S, Cordes J; COMBINE Study Group. Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. Lancet Psychiatry. 2022 Apr;9(4):291-306. doi: 10.1016/S2215-0366(22)00032-3. Epub 2022 Mar 8. PMID: 35276079. 6: Zangani C, Giordano B, Stein HC, Bonora S, D'Agostino A, Ostinelli EG. Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta-analysis. Hum Psychopharmacol. 2021 Nov;36(6):e2801. doi: 10.1002/hup.2801. Epub 2021 Jun 3. Erratum in: Hum Psychopharmacol. 2022 Mar;37(2):e2831. PMID: 34727399; PMCID: PMC8596405. 7: Kranke P, Bergese SD, Minkowitz HS, Melson TI, Leiman DG, Candiotti KA, Liu N, Eberhart L, Habib AS, Wallenborn J, Kovac AL, Diemunsch P, Fox G, Gan TJ. Amisulpride Prevents Postoperative Nausea and Vomiting in Patients at High Risk: A Randomized, Double-blind, Placebo-controlled Trial. Anesthesiology. 2018 Jun;128(6):1099-1106. doi: 10.1097/ALN.0000000000002133. PMID: 29543631. 8: Zhu MH, Liu ZJ, Hu QY, Yang JY, Jin Y, Zhu N, Huang Y, Shi DH, Liu MJ, Tan HY, Zhao L, Lv QY, Yi ZH, Wu FC, Li ZZ. Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo- controlled trial. Mil Med Res. 2022 Oct 18;9(1):59. doi: 10.1186/s40779-022-00420-0. PMID: 36253804; PMCID: PMC9578180. 9: Mota NE, Lima MS, Soares BG. Amisulpride for schizophrenia. Cochrane Database Syst Rev. 2002;2002(2):CD001357. doi: 10.1002/14651858.CD001357. PMID: 12076408; PMCID: PMC7045777. 10: Lecrubier Y. Amisulpride: progress and outcomes. Curr Med Res Opin. 2002;18 Suppl 3:s18-22. doi: 10.1185/030079902125001083. PMID: 12418608. 11: Sugnet T, Jonovska S, Šendula-Jengić V. Amisulpride Reduces Craving in Patients with GBL Addiction - Case Series and Review of the Literature. Psychiatr Danub. 2021 Spring;33(Suppl 4):1235-1237. PMID: 35354194. 12: Green B. Focus on amisulpride. Curr Med Res Opin. 2002;18(3):113-7. doi: 10.1185/030079902125000363. PMID: 12094819. 13: Fox G, Kranke P. A pharmacological profile of intravenous amisulpride for the treatment of postoperative nausea and vomiting. Expert Rev Clin Pharmacol. 2020 Apr;13(4):331-340. doi: 10.1080/17512433.2020.1750366. Epub 2020 Apr 15. PMID: 32245336. 14: Smyla N, Koch T, Eberhart LH, Gehling M. An overview of intravenous amisulpride as a new therapeutic option for the prophylaxis and treatment of postoperative nausea and vomiting. Expert Opin Pharmacother. 2020 Apr;21(5):517-522. doi: 10.1080/14656566.2020.1714029. Epub 2020 Jan 23. PMID: 31971450. 15: Li L, Li L, Shang DW, Wen YG, Ning YP. A systematic review and combined meta-analysis of concentration of oral amisulpride. Br J Clin Pharmacol. 2020 Apr;86(4):668-678. doi: 10.1111/bcp.14246. Epub 2020 Mar 3. PMID: 32090363; PMCID: PMC7098868. 16: Rittmannsberger H. Amisulpride as an Augmentation Agent in Treatment Resistant Depression: A Case Series and Review of the Literature. Psychiatr Danub. 2019 Jun;31(2):148-156. doi: 10.24869/psyd.2019.148. PMID: 31291218. 17: Peuskens J. Switching to amisulpride. Curr Med Res Opin. 2002;18 Suppl 3:s23-8. doi: 10.1185/030079902125001092. PMID: 12418609. 18: Prasannakumar A, Suhas S, Kumar V. Amisulpride-Induced High Elevation in Prolactin Levels. Prim Care Companion CNS Disord. 2023 Jan 12;25(1):22cr03262. doi: 10.4088/PCC.22cr03262. PMID: 36638538. 19: Silvestre FJ, Silvestre-Rangil J, López-Jornet P. Burning mouth syndrome: a review and update. Rev Neurol. 2015 May 16;60(10):457-63. English, Spanish. PMID: 25952601. 20: Gowda GS, Sastry Nagavarapu LS, Reddy Mukku SS, Farooq Ali S. Amisulpride Induced Oropharyngeal Dyskinesia in a patient with Schizophrenia: A case report and review of literature. Asian J Psychiatr. 2019 Mar;41:78-81. doi: 10.1016/j.ajp.2017.10.010. Epub 2017 Nov 13. PMID: 29146045.